Imigran Fdt (Sumatriptan)

Sumatriptan works by binding to serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve fibers. This action causes vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, interrupting the pain pathway that generates migraine.

The exact dose of Imigran Fdt is determined by the prescribing physician based on the individual’s clinical condition, prior response, and tolerability. Physicians typically start with a single tablet and may repeat the dose after a specified interval if needed, but they set the regimen.

Safety data for sumatriptan in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Imigran Fdt, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imigran Fdt belongs to the triptan class, which is more migraine‑specific than over‑the‑counter analgesics such as NSAIDs. Compared with other triptans, sumatriptan has a well‑established efficacy profile and a rapid onset of action, though individual response and side‑effect tolerance may vary.

Imigran Fdt tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and keep out of reach of children.

Imigran Fdt is taken orally as a whole tablet with a glass of water. It should be swallowed whole, not chewed or crushed, and is usually taken as soon as migraine symptoms begin for optimal effectiveness.

The most serious risks include serotonin syndrome when combined with other serotonergic drugs, severe cardiac events such as myocardial ischemia in patients with underlying heart disease, and rare but potentially life‑threatening allergic reactions. Patients should seek immediate medical attention if they experience chest pain, severe rash, or signs of serotonin excess.

Imigran Fdt should be avoided in patients with uncontrolled coronary artery disease, recent myocardial infarction, history of stroke or transient ischemic attack, severe hypertension, or known hypersensitivity to sumatriptan or any tablet excipients. It is also contraindicated in individuals taking MAO inhibitors or ergot alkaloids.